Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-19T22:41:38.909Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone in the treatment of psychosis; a concise review

Published online by Cambridge University Press:  18 September 2015

J.A. den Boer
Get access Rights & Permissions [Opens in a new window]

Summary

Risperidone (Risperdal®) is a recently developed antipsychotic drug with the combination of serotonin-5HT2A-and dopamine-D2-antagonism (SDA). In patients with schizophrenia, risperidone reduces positive symptoms at least equally effective as haloperidol, however, risperidone has a reduced propensity for the induction of extrapyramidal symptoms.

In addition, available evidence indicates that risperidone may be an effective treatment for negative symptoms. The optimum daily dose range is between 4 and 8 mgfor most patients. In this review article, risperidone is compared with some other (classical and atypical) neuroleptics. In addition, the pharmacological and pharmacokinetic properties of risperidone are reviewed.

Keywords

serotonin-5-HT2Adopamine-D2SDArisperidonechronic schizophrenianegative symptomspositive symptomsextrapyramidal symptomsatypical antipsychoticsSerotonine-5-HT2Adopamine-D2SDArisperidonchronische schizofrenienegatieve symptomenpositieve symptomenextrapiramidale symptomenatypische antipsychotica
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 7 , Issue 3 , September 1995 , pp. 84 - 94
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

In België zijn risperidon en clozapine nog niet als geneesmiddel geregistreerd.

References

Literatuur

1.Heinrich, K, Klieser, E, Lehmann, E, Kinzler, E, Hruschka, H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiat 1994; 18: 129–37.CrossRefGoogle ScholarPubMed
2.Wilms, G, Van Ongeval, C, Baert, AL, Claus, A, Bollen, J, De Cuyper, H, Eneman, M, Malfroid, M, Peuskens, J, Heylen, S. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. Acta psychiat scand 1992; 85: 306–12.CrossRefGoogle ScholarPubMed
3.Min, SK, Rhee, CS, Kim, CE, Kang, DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel-group double-blind comparative trial (in Chinese). Yonsei Med J 1993; 34:179–90.CrossRefGoogle Scholar
4.Chouinard, G, Jones, B, Remington, G, Bloom, D, Addington, D, MacEwan, GW, Labelle, A, Beauclair, L, Arnott, W. A Canadian multicenter placebo-controlled study of fixed dosis of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J clin Psychopharmacol 1993; 13: 25–40.CrossRefGoogle Scholar
5.Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiat 1994; 151: 825–35.Google ScholarPubMed
6.Peuskens, J and the Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol (manuscript in preparation).Google Scholar
7.Claus, A, Bollen, J, De Cuyper, H, Eneman, M, Malfroid, M, Peuskens, J, Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta psychiat scand 1992; 85: 295–305.CrossRefGoogle ScholarPubMed
8.Borison, RL, Pathiraja, AP, Diamond, BI, Meibach, RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213–18.Google ScholarPubMed
9.Høyberg, OJ, Fensbo, C, Remvig, J, Lingjaerde, O, Sloth-Nielsen, M, Salvesen, I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta psychiat scand 1993; 88: 395–402.CrossRefGoogle ScholarPubMed
10.Emsley, RA. Risperidone in the treatment of first admission psychotic patients: an international multicentre double-blind parallel group trial versus haloperidol. Beerse, Belgium: Janssen Research Foundation, 1994.Google Scholar
11.Cesková, E, Svestka, J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121–4.CrossRefGoogle ScholarPubMed
12.Vanden Borre, R, Vermote, R, Buttiens, M, Thiry, P, Dierick, G, Geutjens, J, Sieben, G, Heylen, S. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta psychiat scand 1993; 87: 167–71.CrossRefGoogle ScholarPubMed
13.Roose, K, Gelders, Y, Heylen, S. Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. Acta psychiat belg 1988;88:233–41.Google ScholarPubMed
14.Mesotten, F, Suy, E, Pietquin, M, Burton, P, Heylen, S, Gelders, Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacol 1989; 99: 445–9.CrossRefGoogle ScholarPubMed
15.Desseilles, M, Antoine, J, Pietquin, M, Burton, P, Gelders, Y, Heylen, S. Risperidone in psychotic patients: an open dose-finding study. Psychiat Psychobiol 1990; 5: 319–24.CrossRefGoogle Scholar
16.Gelders, YG, Heylen, SL, Vanden Bussche, G, Reyntjens, AJ, Janssen, PA. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990; 23: 206–11.CrossRefGoogle ScholarPubMed
17.Fujii, Y, Yamashita, I, Yamauchi, T, Toru, M, Yagi, G, Kamijima, K, Yamada, H, Murasaki, M, Miura, S. Efficacy and safety of risperidone in the treatment of chronic schizophrenic inpatients (in Japanese). Jap J clin Psychiat 1993; 22: 101–16.Google Scholar
18.Mizuki, Y, Yamada, M, Sugiyama, K, Okamura, I, Uchiyama, M, Watari, H, Suetsugi, M, Onimura, Y. Efficacy and safety of risperidone fine granules, a new antipsychotic drug, on schizophrenic (in Japanese). Jap J Neuropsychopharmacol 1993; 15: 749–62.Google Scholar
19.Möller, HJ, Pelzer, E, Kissling, W, Riehl, T, Wernicke, T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 1991; 24: 185–9.CrossRefGoogle ScholarPubMed
20.Castelão, JF, Ferreira, L, Gelders, YG, Heylen, SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res 1989;2:411–5.CrossRefGoogle Scholar
21.Meco, G, Bedini, L, Bonifati, V, Sonsini, U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo. Curr ther Res clin Exp 1989;46:876–83.Google Scholar
22.Bersani, G, Bressa, GM, Meco, G, JMarini, S, Pozzi, F. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum Psychopharmacol 1990; 5: 225–31.CrossRefGoogle Scholar
23.Inanaga, K, Miura, C, Kuniyoshi, M, Nakamura, J, Saito, M, Yamamoto, K, Okamoto, K, Fukahori, M, Tagawa, K, Imato, N. Yonesaka, Y. The effect of combination therapy of risperidone in the treatment of schizophrenia. The relationship between the clinical efficacy and the plasma level of monoamine metabolite (in Japanese). Jap J Neuropsychopharmacol 1993; 15: 617–31.Google Scholar
24.Möller, HJ. Open study on the long-term treatment of chronic schizophrenic patients with risperidone (R 64 766). Analysis of efficacy and safety data. Beerse, Belgium: Janssen Research Foundation, 1993: publication no. N94387.Google Scholar
25.Addington, DE, Jones, B, Bloom, D, Chouinard, G, Remington, G, Albright, P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone - a retrospective study. Clin Ther 1993;15:917–26.Google ScholarPubMed
26.Hillert, A, Maier, W, Wetzel, H, Benkert, O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - afunctional approach. Pharmacopsychiatry 1992; 25: 213–7.CrossRefGoogle Scholar
27.Schooler, NR. Negative symptoms in schizophrenia - Assessment of the effect of risperidone. J clin Psychiat 1994; 55(suppl): 22–8.Google ScholarPubMed
28.McEvoy, JP. Efficacy of risperidone on positive features of schizophrenia. J clin Psychiat 1994; 55(suppl): 18–21.Google ScholarPubMed
29.Owens, DGC. Extrapyramidal side effects and tolerability of risperidone - A review. J clin Psychiat 1994; 55(suppl): 29–35.Google ScholarPubMed
30.Möller, HJ, Müller, H. Pharmacotherapy for negative symptoms: methodological problems and developments. In: Kane, JM, ed. Understanding and treating negative symptoms. Proceedings of a symposium during the 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, 1994: 22–30.Google Scholar
31.Lindström, E, Von Knorring, L. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 1994; 27: 108–13.CrossRefGoogle ScholarPubMed
32.Lindström, E, Von Knorring, L, Eberhard, G. Studies of selected outcome-related clinical parameters following short-term and long-term treatment with risperidone (Abstract). Neuropsychopharmacol 1994; 10 (suppl 3, part 2): 150S.Google Scholar
33.Meco, G, Alessandria, A, Bonifati, V, Giustini, P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343:1370–1.CrossRefGoogle ScholarPubMed
34.Ford, B, Lynch, T, Greene, P. Risperidone in Parkinson's disease. Lancet 1994; 344:681.CrossRefGoogle ScholarPubMed
35.Nyberg, S, Farde, L, Eriksson, L, Halldin, C, Eriksson, B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidon. Psychopharmacol 1993; 110: 265–72.CrossRefGoogle Scholar
36.Mok, H, Yatham, LN. Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiat 1994; 151: 1393–4.Google ScholarPubMed
37.Daniel, DG. Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders. Biol Psychiat 1994; 35:667.CrossRefGoogle Scholar
38.Lee, H, Ryan, J, Mullett, G, Lawlor, BA. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol clin Exp 1994; 9: 303–5.CrossRefGoogle Scholar
39.Tomsic, J. Neuroleptic malignant syndrome caused by risperidone. Poster at the 25th annual professional practice conference of the Canadian Society of Hospital Pharmacists. Toronto, Ontario, 1994.Google Scholar
40.Webster, P, Wijeratne, C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994; 344: 1228–9.CrossRefGoogle ScholarPubMed